All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-07-26T09:38:12.000Z

Visual abstract | Phase I/II trial of SAR443579 in patients with R/R AML, B-ALL, or HR-MDS

Jul 26, 2023
Share:
Learning objective: After reading this visual abstract, learners will be able to cite a new development in the treatment of R/R AML.

The AML Hub is pleased to present a visual abstract summarizing the preliminary safety and efficacy results from the phase I/II trial (NCT05086315) investigating SAR443579 (SAR’579), a trifunctional anti-CD123 NKp46×CD16 natural killer cell engager, in patients with relapsed/refractory acute myeloid leukemia.1,2 

Preliminary results from this trial were presented by Stein1,2 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2023 Hybrid Congress. No dose-limiting toxicities were identified. Based on the results of this analysis, the study protocol was amended to assess a higher dose of SAR’579.1,2

Visual Abstract

To download this visual abstract, click below.

Download here

  1. Stein AS. A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia. Oral abstract #7005. 2023 American Society of Clinical Oncology Annual Meeting; Jun 2, 2023; Chicago, US.
  2. Stein AS. A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia. Poster #P494. European Hematology Association 2023 Hybrid Congress; Jun 9, 2023; Frankfurt, DE.

Newsletter

Subscribe to get the best content related to AML delivered to your inbox